Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 143 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: IV iron Clear all

Conditions: Obstetric Labor Complications
Interventions: Ferric derisomaltose; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glioblastoma
Interventions: Biospecimen Collection, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Diffusion-Relaxation Correlation Spectrum Imaging, Electronic Health Record Review, Ferumoxytol, Magnetic Resonance Imaging; Procedure · Other · Drug + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Iron Deficiency, Fibromyalgia
Interventions: Injectafer, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions: Guadecitabine, Treatment Choice; Drug · Other
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 22
States / cities: Duarte, California • Rancho Mirage, California • Fleming Island, Florida + 18 more

Conditions: Patients With Chemotherapy Induced Anemia (CIA)
Interventions: Monofer(R); Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Baltimore, MD, Maryland • Canton, Ohio

Conditions: IDA - Iron Deficiency Anemia, Anemia, Iron Deficiency Anemia, Anemia, Iron Deficiency
Interventions: Ferric derisomaltose, NovaFerrum; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 16 Years to 60 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Duarte, California • Los Angeles, California

Conditions: Iron Deficiency Anemia (IDA)
Interventions: Not listed
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose, placebo; Biological · Dietary Supplement · Drug + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: HIV Dementia
Interventions: Ferumoxytol; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 19 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Iron-refractory, Iron-deficiency Anemia (IRIDA)
Interventions: Triferic, Fer-In-Sol, Shohl's solution; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Dialysis, Anemia
Interventions: Roxadustat, Oral Iron, IV Iron; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Northridge, California • Yuba City, California • Detroit, Michigan

Conditions: Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD)
Interventions: Ferumoxytol, Iron Sucrose; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 38
States / cities: Pine Bluff, Arkansas • Azusa, California • Beverly Hills, California + 32 more

Conditions: Anemia
Interventions: Ferric Carboxymaltose, Standard Medical Care (SMC); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: Female only
Enrollment: 2,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Iron Deficiency Anemia of Pregnancy, Iron Malabsorption
Interventions: Iron dextran, Ferrous sulfate 325mg; Drug
Lead sponsor: Indiana University; Other
Eligibility: Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Indianapolis, Indiana • St Louis, Missouri

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation; Biological · Other · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 30 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Anemia, Iron Deficiency Anemia
Interventions: Treatment with oral sucrosomial iron, Treatment with intravenous iron; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: IDH Wild Type Glioblastoma
Interventions: ¹⁸F-Fluoromisonidazole, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Oxygen Therapy, Ferumoxytol, Gadolinium; Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, FCM; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 100
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 83 more

Conditions: Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
Interventions: 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, High Field Strength Magnetic Resonance Imaging, Susceptibility Weighted Imaging; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Restless Legs
Interventions: Ferric Carboxymaltose (FCM), Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Iron Deficiency Anemia, Pregnancy
Interventions: Ferric derisomaltose, Ferrous sulfate; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more

Conditions: Glioblastoma
Interventions: Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab; Drug · Other · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Monoferric for Prenatal Iron Deficiency

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

Iron Deficiency Anemia (IDA) and the Brain

Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Sucrosomial Vs Intravenous Iron for Preoperative Anemia

Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Feasibility of FMISO in Brain Tumors

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Intravenous Iron Metabolism in Restless Legs Syndrome

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma